US 2004/0006205 A1Published application

Therapeutic polypeptides, nucleic acids encoding same, and methods of use

OwnerLi Li, Valerie Gerlach +25inventors

InventorsLi Li, Valerie Gerlach, Xiaohong Liu, Charles E. Miller, Kimberly A. Spytek, Bryan D. Zerhusen, Carol E. A. Pena, Suresh G. Shenoy, Haihong Zhong, Glennda Smithson, Stacie J. Casman, Ferenc L. Boldog, Edward Z. Voss, Corine A. Vernet, John R. MacDougall, Luca Rastelli, David W. Anderson, Mei Zhong, Peter S. Mezes, Katarzyna Furtak, Meera Patturajan, Catherine E. Burgess, Uriel M. Malyankar, Richard A. Shimkets, Raymond J. Taupier JR., Schlomit Edinger, Ann Mazur

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Claims32

Dependent claims

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 45;
b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 45, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
c) the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 45;
d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 45, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
and
e) a fragment of any of a) through d).

3 more elements

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

a) a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 45;
b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 45, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
c) the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 45;
d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 45, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 45, or any variant of the polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed;
and
f) the complement of any of the nucleic acid molecules.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/115,479Filed 2 Apr 2002
Priority: 3 Apr 2001
Published: 8 Jan 2004
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 14/47
From vertebrates: from mammals
A61P 3/00
Drugs for disorders of the metabolism
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents
A61P 3/06
Drugs for disorders of the metabolism: antihyperlipidemics

Family

Application60/281,136Us provisional application · filed 3 Apr 2001
Application60/281,863Us provisional application · filed 5 Apr 2001
Application60/281,906Us provisional application · filed 5 Apr 2001
Application60/282,934Us provisional application · filed 10 Apr 2001
Application60/283,687Us provisional application · filed 13 Apr 2001
Application60/283,657Us provisional application · filed 13 Apr 2001
Application60/283,678Us provisional application · filed 13 Apr 2001
Application60/283,710Us provisional application · filed 13 Apr 2001
Application60/284,234Us provisional application · filed 17 Apr 2001
Application60/285,325Us provisional application · filed 19 Apr 2001
Application60/285,609Us provisional application · filed 20 Apr 2001
Application60/285,748Us provisional application · filed 23 Apr 2001
Application60/285,890Us provisional application · filed 23 Apr 2001
Application60/286,068Us provisional application · filed 24 Apr 2001
Application60/287,213Us provisional application · filed 27 Apr 2001
Application60/288,509Us provisional application · filed 3 May 2001
Application60/294,495Us provisional application · filed 30 May 2001
Application60/294,801Us provisional application · filed 31 May 2001
Application60/309,216Us provisional application · filed 31 Jul 2001
Application60/324,775Us provisional application · filed 25 Sep 2001
Application60/333,900Us provisional application · filed 28 Nov 2001
US 2004/0006205 A1This patent

From the US filing history. Foreign family members aren’t listed.